{"id":1828,"date":"2021-03-16T11:41:42","date_gmt":"2021-03-16T11:41:42","guid":{"rendered":"https:\/\/touchimmunology.com\/?post_type=media_gallery&#038;p=1828"},"modified":"2021-03-16T11:45:35","modified_gmt":"2021-03-16T11:45:35","slug":"jonathan-bernstein-aaaai-2021-hereditary-angioedema-prevalence-pathogenesis-and-treatment-options-part-1","status":"publish","type":"media_gallery","link":"https:\/\/touchimmunology.com\/dermatological-conditions\/conference-hub\/jonathan-bernstein-aaaai-2021-hereditary-angioedema-prevalence-pathogenesis-and-treatment-options-part-1\/","title":{"rendered":"Jonathan Bernstein, AAAAI 2021: Hereditary Angioedema &#8211; Prevalence, Pathogenesis, and Treatment Options"},"content":{"rendered":"<p>touchIMMUNOLOGY caught up with <strong>Jonathan Bernstein<\/strong> (University of Cincinnati; Bernstein Allergy Group, Bernstein Clinical Research Center, Cincinnati, OH, USA) to discuss the prevalence of hereditary angioedema, lanadelumab as a treatment option, and the current challenges faced by patients.<\/p>\n<p>The abstract \u2018<a href=\"https:\/\/els-jbs-prod-cdn.jbs.elsevierhealth.com\/pb\/assets\/raw\/Health%20Advance\/journals\/ymai\/AAAAI_2021_Abstracts_313-556.pdf\" rel=\"nofollow noopener\" target=\"_blank\">Efficacy of Lanadelumab in Hereditary Angioedema Patients With and Without Prior Use of Long-Term Prophylaxis: Final Results From the HELP Open-Label Extension Study<\/a>.\u2019 (ABSTRACT NUMBER: 462) was presented at the American Academy of Allergy, Asthma &amp; Immunology Virtual Annual Meeting, February 26-March 1, 2021.<\/p>\n<p><strong>Questions<\/strong>:<\/p>\n<ol>\n<li>Could you give us a brief overview of hereditary angioedema (HAE), its prevalence and pathogenesis? (0:20)<\/li>\n<li>Where does lanadelumab sit in the current treatment paradigm for the prevention of HAE attacks? (2:05)<\/li>\n<li>What are the challenges in individualised prescribing of lanadelumab for the prevention of HAE attacks? (3:50)<\/li>\n<\/ol>\n<p><strong>Disclosures<\/strong>: Jonathan Bernstein has nothing to disclose in relation to this video.<\/p>\n<p><strong>Support<\/strong>: Interview and filming supported by Touch Medical Media.<\/p>\n<p><em><strong>Filmed as a highlight of AAAAI 2021 (Virtual).<\/strong><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>touchIMMUNOLOGY caught up with Jonathan Bernstein (University of Cincinnati; Bernstein Allergy Group, Bernstein Clinical Research Center, Cincinnati, OH, USA) to discuss the prevalence of hereditary angioedema, lanadelumab as a treatment option, and the current challenges faced by patients. The abstract \u2018Efficacy of Lanadelumab in Hereditary Angioedema Patients With and Without Prior Use of Long-Term Prophylaxis: [&hellip;]<\/p>\n","protected":false},"featured_media":1826,"template":"","class_list":["post-1828","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-dermatological-conditions","video_categories-aaaai-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/1828","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":6,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/1828\/revisions"}],"predecessor-version":[{"id":1835,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/1828\/revisions\/1835"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media\/1826"}],"wp:attachment":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media?parent=1828"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}